Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest update is out from Zura Bio ( (ZURA) ).
Zura Bio Limited, a clinical-stage immunology company, is set to engage with investors at two major conferences in November 2024. The company, known for developing dual-pathway antibodies for autoimmune diseases, will participate in the Guggenheim Healthcare Innovation Conference in Boston and the Jefferies London Healthcare Conference. These events provide a platform for Zura Bio to showcase its promising therapeutic developments, including tibulizumab, crebankitug, and torudokimab, which are poised for Phase 2 trials.
For detailed information about ZURA stock, go to TipRanks’ Stock Analysis page.
